

P-2020/45664

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIRECCIÓN DE NUEVAS CREACIONES

E. S. D.

Re: Expediente No. **NC2020/0011442**

Solicitud de patente a nombre de **UNIVERSITY OF LEICESTER y
OMEROS CORPORATION**

Yo, CAROLINA DAZA MONTALVO identificada como aparece al pie de mi firma, domiciliada en la Carrera 11 No. 86-53, obrando como apoderada de la sociedad UNIVERSITY OF LEICESTER y OMEROS CORPORATION domiciliadas en Inglaterra y Estados Unidos de América, respectivamente, solicitantes de la patente de la referencia, en respuesta al oficio No. **12003** notificado electrónicamente el 25 de septiembre de 2020, relacionado con los requerimientos de forma de la solicitud, atentamente me permito presentar la siguiente información:

1. Figuras

A fin de dar cumplimiento con los requerimientos formales de la solicitud, se adjunta un el juego de figuras conformados por 73 figuras (93 páginas).

Se solicita se adjuntar dichas figuras al expediente, solicitud que cuenta con los requerimientos para ser aceptada.

2. Anexos

- Juego de figuras

Señora Directora,



CAROLINA DAZA MONTALVO

C.C. 66.783.790 de Palmira Valle

TP-141563 CSJ

notificaciones@clarkemodet.com.co




FIG. 1

FIG. 2

MASP 1 y 3




FIG. 3

MA SP-3 en humanos (SEQ ID NO:2)

MRWLLLYVALCFSLKASAHTELVNMFQIQSPGYPDSYPSDSEVTWNI TVPDGFR IKLYFMHFNLESSYLCEYD
YVKVETEDQVLATFCGRETTDTEQTPGQEVVLSPGSFMSITFRSDFSNEERFTGFDAHYMAVDVDECKEREDEELS
CDHYCHNYIGGYCSCRFGYILHTDNRTCRVECDNLFTQRTGVTITSPDFPNPYPKSSECLYTIELEEGFMVNLQF } CUB1-EGF-CUB2
EDIFDIEDHPEVPCPYDIKIKVGPKVLGPFCEGEKAPEPISTQSHSVLILFHSDNSGENRGWRLSYRAAG
NECP ELQPPVHGKIEPSQAKYFFKDQVLVSCDTGYKVLKDNVEMDTFQIECLKDGTWSNKIPTCKIIVDCRAPGELE
HGLITFSTRNNLITYKSEIKYSCQEPYKMLNNTGIYTCSAQGVWMNKVLGRSLPTCLPECGQPSRSLPSLVKRI
IGGRNAEPGLFPWQALIVVEDTSRVPNDKWFEGSGALLSASWILTAHVLRSQRRDITVIPVSKEHVTIVLGLHDVR } ECP1-CCP2-SP
DKSGAVNSSAARVVVHPDENIQNYNHDI ALVQLQEPVPLGPHVMPVCLPRLEPEGPAPHMLGLVAGWGISNPNTV
DEIISGTRT LSDVLQYVKLPVVPHPAECKTSYESRSGNYSVTENMFCAGYVEGKDTCLGDSGGA FVIFDDLSQRW
VVQGLVSWGPEECGSKQVYGVTYTKVSNYVDWVWEQMLPQSVVEPQVER

FIG. 4

[illegible]

FIG. 5

Dominio de la Proteasa de serina (SP) de MASP-3: alineamiento de varias especies

```

1      80
Human_M3_SP  IIGGRNAEEGLFFWQALIVVEDTSRVENDKNWFGSALLSASWILTAAHVLRSQRDDTIVPSKEHVTIVLGLHDVRDKS
Cyno_M3_SP   .....E.....
Rabbit_M3_SP .....E.....N.....R.....
Rat_M3_SP    .....I.....N.....D.....
Mouse_M3_SP  .....E.....N.....
Chicken_M3_SP.....F.....M.....D.V.....K.....A.....N.L

81      160
Human_M3_SP  GAVNSSAARVVLHPDENIQNNHDIALVQLQEEVPLGPHVMEVCLPRLEPE--GPAPHMLGLVAGNGISNPNVTVDKIS
Cyno_M3_SP   .....S.....
Rabbit_M3_SP .....I.....P.....Y.....
Rat_M3_SP    .....A.....I.....P.....I.....
Mouse_M3_SP  .....K.....A.....I.....P.....L.....
Chicken_M3_SP.....RTVE.II.E.D.....K.K.K.TM.NY..I..QF.H.LE..H.NT.....I.....

161      240
Human_M3_SP  SGTRTISDVLYVVKLFPVVPFAECKTSYVESRSGNYSVTENMFCAGYVEGGKDTCLGDSGGAFVIEDDLSRWVQGLVSWG
Cyno_M3_SP   .....L.....
Rabbit_M3_SP .....I.....L.....R.....A.....
Rat_M3_SP    .....S.....A.....EM.....A.....
Mouse_M3_SP  .....S.....A.....EM..H..A.....
Chicken_M3_SP.....M.....I.....L.....Q.PGTR..A.....

241      283
Human_M3_SP  GPEECGSKQVYGVTYKVSNVVDWVWEQMGLPQ-SVVEPQVER aa450-728 of SEQ ID NO:2
Cyno_M3_SP   .....S...--GRAPGGIVS aa450-728 of SEQ ID NO:7
Rabbit_M3_SP .....S...--GLG.L... aa450-728 of SEQ ID NO:6
Rat_M3_SP    .....LL.E.NS.R--G.R.L... aa455-733 of SEQ ID NO:4
Mouse_M3_SP  .....L..E.NS.R--A.RDL... aa455-733 of SEQ ID NO:3
Chicken_M3_SP.....EKNT.SSERWTFD.EL.. aa448-730 of SEQ ID NO:5

```

FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10





FIG. 11






FIG. 13




FIG.14

Los ratones deficientes en MASP-1/3 no son deficientes en la actividad funcional de LP




FIG. 15




FIG. 16




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 18A




FIG. 18B




FIG. 18 C




FIG. 19




FIG. 20
Hemólisis de RBC de murino recubierto de manano por suero humano




FIG. 21




FIG. 22




FIG. 23




FIG. 24B




FIG. 24A




FIG. 25




FIG. 26A

1	65
VH	AVTLDESGGGLQTPGGALS LVCKASGFTFSNAMGMRQAPGKGLEWVAGID-DDGSGTRYAPAV
M3J5	G.....Y.....M.....Y.....R-S...F.L..T..
M3M1	G.....D.....YQ.N.I.....F..A.N-RF.NS.GHGA..
D14	Y.....Y.H.....Y-KS.A..N.....
1E10	YD.V.....F.....SRN..RY.E.GS..

66	129
VH	KGRAT I SRDNGQSTLRQLNLLRAEDTGTYYCTKCA YSS-GCDYEGG--Y I DAWGHGTEV I VSS
M3J5	V.....A..F..RSG-----NV...-D.....
M3M1	...D...V...S.....A..GV.GYC.SYSCC.VDT.....
D14	V.....A..TTG.GCSSG.RAE--.....
1E10	V.....A..ARD.GG.-AYWFDA.--Q.....

FIG. 26B

	1	54
VL	ALTQPASVSANLGGTVKITCSGGGS-YAGSYYYGWWQKSPGSAPVTVIY	DNDK
M3J5	P.E.....Y.G.....A.....L.....	Y.N.
M3M1	P.E.....-.....A.....L.....	Y.N.
D14	P.E.....-.....A.....L.....	Y.N.
1E10	P.E.....-.....A.....L.....	Y.N.

	55	108
VL	RPSDIPSRFSGSLSGSTNTLTITGVRADDEAVYFCGSADNSGAIFGAGTTLTVL	
M3J5		
M3M1		
D14		
1E10		

FIG. 27




FIG. 28A




FIG. 28B





FIG. 29

Escisión del Factor B en respuesta a *S. aureus*



La complementación de suero 3MC con MASP-3 recombinante aumenta la escisión del Factor B.

FIG. 30

MASP-3 escinde directamente pro-Bf




FIG. 31




FIG. 32




FIG. 33

Inhibición parcial de la escisión dependiente de
MASP-3 de Pro-Df con anticuerpos MASP-3




FIG. 34




FIG. 35A




FIG. 35B




FIG. 35C




FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42




FIG. 43




FIG. 44




FIG. 45

Estudio de PNH en curso

Supervivencia de RBC




FIG. 46

Supervivencia de RBC en Ratones tratados




FIG. 47




FIG. 48




FIG. 49A

MA SP-3 mAbs de alta afinidad: Regiones variables de la cadena pesada

VE	Kabat	35	50	65	95	102							
1F3_VH	QVQLKQSGPELVHFGASVNL	-----T	SNIDINWVQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:25)
1A10_VH	QVQLKQSGPELVHFGASVNL	-----T	SNIDINWVQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:27)
4B6_VH	QVQLKQSGPELVHFGASVNL	-----T	SNIDINWVQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:26)
4D8_VH	QVQLKQSGPELVHFGASVNL	-----T	TODINWVQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	AVSS	(SIN:24)
1G4_VH	QVQLKQSGPELVHFGASVNL	-----T	GVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:21)
1B51_VH	QVQLKQSGPELVHFGASVNL	-----T	GRVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:30)
2F5_VH	EVQLQDSGPELVHFGASVNL	-----T	SYVITWVQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:36)
1B29_VH	QVQLKQSGPELVHFGASVNL	-----T	AYVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:35)
1B11_VH	QVQLKQSGPELVHFGASVNL	-----T	DYVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:37)
2F2_VH	QVQLKQSGPELVHFGASVNL	-----T	TYVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:38)
1B6_VH	QVQLKQSGPELVHFGASVNL	-----T	TYVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:39)
2D7_VH	EVQLQDSGPELVHFGASVNL	-----T	DYVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:33)
49C11_VH	QVQLKQSGPELVHFGASVNL	-----T	DYVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:34)
1E7_VH	QVQLKQSGPELVHFGASVNL	-----T	PRVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:32)
10D12_VH	QVQLKQSGPELVHFGASVNL	-----T	SYVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:39)
38C1_VH	QVQLKQSGPELVHFGASVNL	-----T	SYVIEIWIWQR	FGGLENIWQ	IVPFGSGTNY	NEKFTDQKATL	TVTVSSSTAY	VELSLSLSED	SAVTFCSGVE	D-----	-SYNGQGTIV	TVSS	(SIN:29)

FIG. 49B

MASP-3 mAbs de alta afinidad: Regiones variables de la cadena ligera

VL	Kabat	24	34	50	56	89	97
1F9_VL	DIVMTQSPSS LAVSAGEKVT MSCKSSQSLL ISRTTRKNTLS	WYQKFGQSP	KLLIYWASTR	ESGVPRFTG	SGSGIDFTLT	ISSVQAE ~~DLA~~ VYVCKOSYNL	---YTFEGGGT KLEIKR (SIN:41)
4B6_VL	DIVMTQSPSS LAVSAGEKVT MSCKSSQSLL ISRTTRKNTLS	WYQKFGQSP	KLLIYWASTR	ESGVPRFTG	SGSGIDFTLT	ISSVQAE ~~DLA~~ VYVCKOSYNL	---YTFEGGGT KLEIKR (SIN:42)
4D6_VL	DIVMTQSPSS LAVSAGEKVT MTCKSSQSLL NSRTTRKNTLS	WYQKFGQSP	KLLIYWASTR	ESGVPRFTG	SGSGIDFTLT	ISSVQAE ~~DLA~~ VYVCKOSYNL	---YTFEGGGT KLEIKR (SIN:40)
13B1_VL	DIVMTQSPSS LAVSAGEKVT MSCKSSQSLL NSRTTRKNTLS	WYQKFGQSP	KLLIYWASTR	ESGVPRFTG	SGSGIDFTLT	ISSVQAE ~~DLA~~ VYVCKOSYNL	---PTFEGGGT KLEIKR (SIN:45)
1G4_VL	DIVMTQSPSS LPSVLGEQAS ISCRSSQSLV QS-NGNTYTL	WYQKFGQSP	KLLIYKVSNR	FSGVPRFSG	SGSGIDFTLK	ISRVAEDLG	VYVCSOSTEV P--PTFEGGGT KLEIKR (SIN:46)
49C11_VL	DIVMTQSPSS LPSVLGEQAS FSCRSSQSLI HS-NGNTYTL	WYQKFGQSP	KLLIYKVSNR	FSGVPRFSG	SGSGIDFTLK	ISRVAEDLG	VYVCSOSTEV P--WTFEGGGT KLEIKR (SIN:49)
10D12_VL	DIVMTQSPSS LSVTIQGPAS ISCKSSQSLL DS-DGKTYLN	WYQKFGQSP	KLLIYLVSKL	DSGVPRFTG	SGSGIDFTLK	ISRVAEDLG	VYVWOGSTEV P--WTFEGGGT KLEIKR (SIN:43)
35C1_VL	DIVMTQSPSS LSVTIQGPAS ISCKSSQSLL DS-DGKTYLN	WYQKFGQSP	KLLIYLVSKL	DSGVPRFTG	SGSGIDFTLK	ISRVAEDLG	VYVWOGSTEV P--YTFEGGGT KLEIKR (SIN:44)
2F5_VL	DIVMTQSPSS LSVTIQGPAS ITCKASQNV- -----GTAVA	WYQKFGQSP	KLLISSASNR	YTGVPDRFTG	SGSGIDFTLT	ISNVQSEDVA	DYVCOQINSY P--LTFEGAGT KLEIKR (SIN:51)
1B11_VL	DIVMTQSPSS LSVTIQGPAS VTCKASQNV- -----GPNVA	WYQKFGQSP	KLLIYVSAYR	YSGVPRFTG	SGSGIDFTLT	ISNVQSEDVA	DYVCOQINSY P--LTFEGAGT KLEIKR (SIN:52)
15D9_VL	DIVMTQSPSS LSVTIQGPAS VTCKASQNV- -----GPNLA	WYQKFGQSP	KLLIYVSAYR	FSGVPRFTG	SGSGIDFTLT	ISNVQSEDVA	DYVCOQINSY P--PTFEGGGT KLEIKR (SIN:50)
11B6_VL	DIVMTQSPSS LSVTIQGPAS VTCKASQNV- -----GPTVA	WYQKFGQSP	KLLIYVSAYR	YSGVPRFTG	SGSGIDFTLT	ISNVQSEDVA	DYVCOQINSY P--PTFEGGGT KLEIKR (SIN:54)
2F2_VL	DIVMTQSPSS LSVTIQGPAS VTCKASQNV- -----GTAVA	WYQKFGQSP	KLLIYVSAYR	YSGVPRFTG	SGSGIDFTLT	ISNVQSEDVA	DYVCOQINSY PRALTFEGAGT KLEIKR (SIN:53)
1E7_VL	DIVMTQSPSS LSVTIQGPAS FSCRASQSI- -----GTSIH	WYQKFGQSP	KLLIYVSAYR	ISGVPDRFTG	SGSGIDFTLS	ISNVQSEDVA	DYVCOQINSY P--YTFEGGGT KLEIKR (SIN:47)
2D7_VL	DIVMTQSPSS LSVTIQGPAS ISCRASQSI- -----SNFLN	WYQKFGQSP	KLLIYVSAYR	ESGVPRFTG	SGSGIDFTLS	ISNVQSEDVA	DYVCOQINSY P--WTFEGGGT KLEIKR (SIN:48)

FIG. 50A




FIG. 50B

Dendrograma de las regiones VL de MASP-3 mAbs de alta afinidad




FIG. 51A

Unión de MASP-3 mAbs recombinante purificado a MASP-3 humano




FIG. 51B




FIG. 51C




FIG. 51D




FIG. 52

Unión de MASP3 mAbs a MASP-3 de ratón de extensión completa




FIG. 53

Inhibición de la escisión del tripéptido de fluorogénico
por MASP-3 mAbs




FIG. 54

MAASP-3 mAbs de alta afinidad inhibe la Escisión del CFD por rMAASP-3





FIG. 55A


Inhibición de Depósito del Factor Bb en Zimosan por MASP-3 mAbs



	mAb 1F3	mAb 1G4	mAb 2D7	mAb 4B6
IC50 (nM)	0.1	1.1	3.5	0.2

FIG. 55B


Inhibición de Depósito del Factor Bb en Zimosan por MASP-3 mAbs



	mAb 4D5	mAb 10D12	mAb 13B1
IC50 (nM)	0.4	0.5	0.3

FIG. 56A


Inhibición de la lisis de eritrocitos de conejo por MASP-3 mAbs



	mAb 1A10	mAb 1F3	mAb 1G4	mAb 2F2	mAb 4B6	mAb 4D5
IC50 (nM)	0.2	0.2	-	0.8	0.2	0.1


FIG. 56B

Inhibición de la lisis de eritrocitos de conejo por MASP-3 mAbs



	mAb 1B11	mAb 1E7	mAb 1G4	mAb 2D7	mAb 2F5
IC50 (nM)	-	-	2.7	5.4	0.9

FIG. 57
Factor D en Suero 3MC






FIG. 59

Estado del fragmento Ba del Factor B en Ratones
tratados con mAb 10D12




FIG. 60

El suero de los ratones tratados con mAb 10D12 muestran inhibición de la hemólisis




FIG. 61A
El análisis competitivo de enlace identifica MASP-3 mAbs (IgG4) que bloquea la interacción entre mAb 4D5 (IgG1) y MASP-3




FIG. 61B
El análisis competitivo de enlace identifica MASP-3 mAbs (IgG4) que bloquea la interacción entre mAb 10D12 (IgG1) y MASP-3




FIG. 61C
El análisis competitivo de enlace identifica MASP-3 mAbs (IgG4) que bloquea la interacción entre mAb 13B1 (IgG1) y MASP-3




FIG. 61D
El análisis competitivo de enlace identifica MASP-3 mAbs (IgG4) que bloquea la interacción entre mAb 1F3 (IgG4) y MASP-3




FIG. 61E
El análisis competitivo de enlace identifica MASP-3 mAbs (IgG4) que bloquea la interacción entre mAb 1G4 (IgG1) y MASP-3





FIG. 62

Regiones de contacto en MASP-3 por el MASP-3 mAbs




H=497
D=553
S=664

Nota : #9 a #23 "SIN" se refiere a SEQ ID NO:s

FIG. 63A

Regiones de contacto en MASP-3 humano para mAbs 1F3, 4B6, 4D5 y 1A10



SEQ ID NO:9 = aa residuos 498-509 de MASP-3
SEQ ID NO:11= aa residuos 544-558 de MASP-3
SEQ ID NO:13= aa residuos 639-649 de MASP-3
SEQ ID NO:14= aa residuos 704-713 de MASP-3


FIG. 63B

Regiones de contacto en MASP-3 humano para mAbs 10D12




SEQ ID NO:9 = aa residuos 498-509 de MASP-3

FIG. 64
Regiones de contacto en MASP-3 humano para mAb 13B1



SEQ ID NO:10= aa residuos 494 hasta 508 de MASP-3
SEQ ID NO:12= aa residuos 626 hasta 638 de MASP-3


FIG. 65
Regiones de contacto en MASP-3 humano para mAb 1B11



SEQ ID NO:16= aa residuos 435-447 de MASP-3
SEQ ID NO:17= aa residuos 454-464 de MASP-3
SEQ ID NO:21= aa residuos 583-589 de MASP-3
SEQ ID NO:22= aa residuos 614-623 de MASP-3


FIG. 66

Regiones de contacto en MASP-3 humano para mAb 1E7, 1G4 y 2D7



SEQ ID NO:17= aa residuos 454 hasta 464 de MASP-3
SEQ ID NO:19= aa residuos 514 hasta 523 de MASP-3
SEQ ID NO:23= aa residuos 667 hasta 678 de MASP-3

FIG. 67
Regiones de contacto en MASP-3 humano para mAb 15D9 y 2F5



SEQ ID NO:17= aa residuos 454 hasta 464 de MASP-3
SEQ ID NO:18= aa residuos 479 hasta 493 de MASP-3
SEQ ID NO:20= aa residuos 562 hasta 571 de MASP-3
SEQ ID NO:23= aa residuos 667 hasta 678 de MASP-3

FIG. 68

EAE en Hembras B6 con 13B1, control de isotipos y anticuerpos anti-Factor B




FIG. 69

h13B1X- Animales tratados





FIG. 70

Depósito de Bb en Zimosan








FIG. 72A




FIG. 72B




FIG. 72C




FIG. 73
Análisis de Pro-Df/Df maduro en Suero de Mono tratado con 13B1X

